Kinfo
Legend Biotech Corporation ADR logo

Legend Biotech Corporation ADR

LEGNNASDAQHealthcare·US · USD
$17.80
-0.82 (-4.40%)
Prices as of October 12, 2026 · market closed

Price

Key statistics

Valuation
Market cap3.46B USD
Enterprise value2.92B USD
Trailing P/E-10.98
Forward P/E17.73
PEG ratio0.09
Price / sales2.85
Price / book2.93
Profitability
Gross margin64.54%
Operating margin14.89%
Profit margin-7.20%
Return on assets-1.92%
Return on equity-8.08%
Income (TTM)
Revenue1.27B USD
Gross profit719.30M USD
EBITDA-41.60M USD
Net income-91.50M USD
Diluted EPS-$0.52
Rev. growth (YoY)51.90%
Balance sheet
Total cash964.60M USD
Total debt278.20M USD
Debt / equity22.63
Current ratio3.04
Book value / share$6.35
Cash flow (TTM)
Operating cash flow-89.40M USD
Levered free cash flow27.19M USD
Shares & price
Shares outstanding387.54M
Float193.54M
Held by institutions56.85%
Beta0.57
50-day MA$19.75
200-day MA$22.33
52-week high$37.50
52-week low$16.24
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-282.302.54+10.43%2026-08-110.280.32+14.29%2026-05-040.780.87+11.54%2026-03-100.19-0.16−184.21%2026-01-152.983.14+5.37%
About Legend Biotech Corporation ADR

Legend Biotech Corporation ADR is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing cell therapies for oncology and other serious diseases. The company’s work centers on advanced immunotherapy platforms, including chimeric antigen receptor T-cell approaches and other cellular therapies designed to target hard-to-treat cancers. Its portfolio is led by CARVYKTI, a BCMA-directed CAR-T therapy used in multiple myeloma, and it also supports additional investigational cell therapy programs across hematologic and solid tumor settings. Legend Biotech serves patients and healthcare providers through a global footprint spanning the United States, China, and Europe, combining research, manufacturing, and commercialization capabilities within a single operational model. As an ADR, Legend Biotech Corporation ADR provides market access to a company positioned at the intersection of biotechnology innovation and specialty cancer treatment.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ying Huang Ph.D.
Employees
2,600
Headquarters
Somerset, NJ, United States

Frequently asked questions about Legend Biotech Corporation ADR